Asciminib Roll-over Study for Chronic Myelogenous Leukemia
This study is for people with Philadelphia chromosome-positive chronic myelogenous leukemia (PH+ CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) who are already taking asciminib, imatinib, nilotinib, or bosutinib in a Novartis-sponsored study. It's designed to let you continue receiving your current treatment if your doctor believes it's still beneficial. The main goal is to understand the long-term safety of these medications by tracking any side effects (adverse events) over 8 years. This study aims to enroll about 347 participants aged 7 to 100 years old.
- Study design
- This is an open-label, multi-center study, meaning both you and your doctors will know which medication you are receiving. It is designed to provide continued treatment to participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for adverse events and serious adverse events for 8 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Asciminib Roll-over Study
At a glance
Conditions
Where it's being run
85 sites across 53 statesStudy leadership
- Novartis Pharmaceuticals · STUDY_DIRECTOR · Novartis Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)8 years
All AEs and SAEs will be tabulated and listed for participants in the Safety Set by treatment group. From day of first administration of study treatment to 30 days after the last study treatment.